These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39226499)

  • 41. Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?
    Mehr SR; Brook RA
    Pharmaceut Med; 2019 Feb; 33(1):1-8. PubMed ID: 31933270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience.
    Bocquet F; Paubel P; Fusier I; Cordonnier AL; Sinègre M; Le Pen C
    Appl Health Econ Health Policy; 2015 Feb; 13(1):47-59. PubMed ID: 25189295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differences Between Managed Care and Fee-for-Service Medicaid in the Use of Generics for High-Rebate Drugs: The Cases of Insulin Glargine and Glatiramer.
    Hernandez I; Gellad WF
    J Manag Care Spec Pharm; 2020 Feb; 26(2):154-159. PubMed ID: 32011961
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reduction of biologic pricing following biosimilar introduction: Analysis across 57 countries and regions, 2012-19.
    Chen HH; Yemeke T; Ozawa S
    PLoS One; 2024; 19(6):e0304851. PubMed ID: 38843282
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.
    Mouslim MC; Trujillo AJ; Alexander GC; Segal JB
    Value Health; 2020 Dec; 23(12):1599-1605. PubMed ID: 33248515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries.
    Lee SM; Jung JH; Suh D; Jung YS; Yoo SL; Kim DW; Kim JA; Suh DC
    BioDrugs; 2019 Aug; 33(4):423-436. PubMed ID: 31201616
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.
    Chai Q; Wen H; Lang Y; Zhang L; Song Y; Liu X
    Clin Drug Investig; 2022 Nov; 42(11):937-947. PubMed ID: 36115003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective.
    Clarke K; Ainslie-Garcia M; Ferko N; Shastri K
    J Med Econ; 2024; 27(1):952-962. PubMed ID: 39015093
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of Uptake and Prices of Biosimilars in the US, Germany, and Switzerland.
    Carl DL; Laube Y; Serra-Burriel M; Naci H; Ludwig WD; Vokinger KN
    JAMA Netw Open; 2022 Dec; 5(12):e2244670. PubMed ID: 36459139
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Economic Impact of Originator-to-Biosimilar Non-medical Switching in the Real-World Setting: A Systematic Literature Review.
    Hillhouse E; Mathurin K; Bibeau J; Parison D; Rahal Y; Lachaine J; Beauchemin C
    Adv Ther; 2022 Jan; 39(1):455-487. PubMed ID: 34780028
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.
    Yang J; Carioto J; Pyenson B; Smith R; Jacobson N; Pittinger S; Shelbaya A
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1642-1651. PubMed ID: 34677089
    [No Abstract]   [Full Text] [Related]  

  • 53. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
    Godman B; Wladysiuk M; McTaggart S; Kurdi A; Allocati E; Jakovljevic M; Kalemeera F; Hoxha I; Nachtnebel A; Sauermann R; Hinteregger M; Marković-Peković V; Tubic B; Petrova G; Tachkov K; Slabý J; Nejezchlebova R; Krulichová IS; Laius O; Selke G; Langner I; Harsanyi A; Inotai A; Jakupi A; Henkuzens S; Garuolienė K; Gulbinovič J; Bonanno PV; Rutkowski J; Ingeberg S; Melien Ø; Mardare I; Fürst J; MacBride-Stewart S; Holmes C; Pontes C; Zara C; Pedrola MT; Hoffmann M; Kourafalos V; Pisana A; Banzi R; Campbell S; Wettermark B
    Biomed Res Int; 2021; 2021():9996193. PubMed ID: 34676266
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.
    Farhat F; Torres A; Park W; de Lima Lopes G; Mudad R; Ikpeazu C; Abi Aad S
    Oncologist; 2018 Mar; 23(3):346-352. PubMed ID: 29284760
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
    Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
    Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
    Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
    Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Outcomes after anti-tumour necrosis factor originator to biosimilar switching in children and young people with juvenile idiopathic arthritis in the UK: a national cohort study.
    Kearsley-Fleet L; Baildam E; Beresford MW; Douglas S; Foster HE; Southwood TR; Hyrich KL;
    Lancet Rheumatol; 2024 Jul; 6(7):e438-e446. PubMed ID: 38843858
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biosimilar Use Among 38 ASCO PracticeNET Practices, 2019-2021.
    Bourbeau B; Lyman GH; Lei XJ; Jones L; Rosenthal J; Kozlik MM; Oettel KR; Tinger A; Page R
    JCO Oncol Pract; 2023 Jul; 19(7):516-522. PubMed ID: 37084324
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.
    Bloomfield D; D'Andrea E; Nagar S; Kesselheim A
    JAMA Oncol; 2022 Apr; 8(4):537-545. PubMed ID: 35113135
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.